Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Skyrocketing Today

By George Budwell – Jul 7, 2020 at 8:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax lands a massive $1.6 billion award from the federal government's Operation Warp Speed program.

What happened

Novavax (NVAX -1.99%), a late-stage vaccine developer, is poised for yet another strong session today. Specifically, the biotech's shares jumped by as much as 35% in premarket trading Tuesday morning. If this latest move northward holds during today's session, Novavax's stock will have risen by an astounding 3,500% for the whole of 2020.  

The catalyst? Ahead of the opening bell, Novavax announced that the federal government -- through the Operation Warp Speed (OWS) program -- awarded the company a staggering $1.6 billion to complete the late-stage development of its COVID-19 vaccine candidate known as NVX-CoV2373. The funding will reportedly be used to support a pivotal-stage trial, along with the production of 100 million doses of NVX‑CoV2373 by January 2021. 

A rocket above the cloud deck.

Image source: Getty Images.

So what

Even though Novavax was initially left out of OWS, the company just landed the biggest award from the program to date. That's definitely a major vote of confidence from the federal government, perhaps indicating that NVX-CoV2373's ongoing early-stage trial is going exceptionally well. 

Now what

Novavax is expected to roll out the vaccine's preliminary immunogenicity and safety results by the end of July. Assuming these data support further development, NVX-CoV2373's all-important disease reduction study (a pivotal Phase 3 trial) should get under way by October.

What this means is that this mid-cap biotech has a good shot at being one of the first companies to bring a COVID-19 vaccine to market, perhaps as early as the middle of 2021. That's a big deal, because the pandemic is showing no signs of slowing down. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$18.20 (-1.99%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.